The Efficacy and Safety of Febuxostat in Korean Patients with Gout

Sung Won Lee

doi:10.4078/jrd.2013.20.5.277

Journal List > J Rheum Dis > v.20(5) > 1064061

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Lee: The Efficacy and Safety of Febuxostat in Korean Patients with Gout

Editorial

J Rheum Dis 2013;20(5):277-279.

Published online: 31 October 2013

DOI: https://doi.org/10.4078/jrd.2013.20.5.277

The Efficacy and Safety of Febuxostat in Korean Patients with Gout

Sung Won Lee

Division of Rheumatology, Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea

Corresponding to : Sung Won Lee, Division of Rheumatology, Department of Internal Medicine, College of Medicine, Dong-A University, 26, Daesingongwon-ro, Seo-gu, Busan 602-715, Korea. E-mail : leesw@dau.ac.kr

Received 4 October 201310 October 2013 Accepted 10 October 2013

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003; 349:1647–55.

2. Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995; 48:1153–8.

3. Lee CH, Sung NY. The Prevalence and Features of Korean Gout Patients Using the National Health Insu-rance Corporation Database. J Rheum Dis. 2011; 18:94–100.

4. Reach G. Treatment adherence in patients with gout. Joint Bone Spine. 2011; 78:456–9.

5. Son KM, Seo YI, Kim IJ, Bae YD, Jung YO, Cha MJ, et al. Adherence to uric acid lowering agent of gouty patients. J Korean Rheum Assoc. 2010; 17:162–7.

6. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. American college of rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012; 64:1431–46.

7. Hamburger M, Baraf HS, Adamson TC 3rd, Basile J, Bass L, Cole B, et al. European League Against Rheumatism. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Postgrad Med. 2011; 123(6 Suppl 1):3–36.

8. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010; 6:30–8.

9. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009; 11:135–40.

10. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450–61.

11. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008; 59:1540–8.

12. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009; 48:188–94.

13. Park SH, Song YW, Park W, Koh EM, Yoo B, Lee SK, et al. The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout. J Rheum Dis. 2013; 20:223–30.

TOOLS

Similar articles